Crystal form and salt form of five-membered-fused six-membered compound, preparation method, pharmaceutical composition, and use

Abstract

A crystal form and salt form of a five- and six-membered compound, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof are disclosed. Specifically, a crystal form and salt form of a five-membered-fused six-membered compound as shown in formula I, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof are disclosed. The crystal form and salt form of the compound have an inhibitory effect on FLT3 and/or IRAK4. The crystal form has a high single melt point, is thermodynamically stable, and has high crystallinity. The crystal form represents good physical and chemical stability under strong illumination, high temperature and high humidity conditions, and the crystal form has weak hygroscopicity.